P883: TARGETING CALCINEURIN/NFATC1 SIGNALING SENSITIZES PROTEASOME INHIBITION TREATMENT IN MULTIPLE MYELOMA

MLA

J. Zhang, et al. “P883: Targeting Calcineurin/Nfatc1 Signaling Sensitizes Proteasome Inhibition Treatment in Multiple Myeloma.” HemaSphere, vol. 6, June 2022, pp. 775–76. EBSCOhost, https://doi.org/10.1097/01.HS9.0000846408.90988.ee.

APA

J. Zhang, X. Luo, T. Xia, K. C. Cheng, & M. H. Ng. (2022). P883: Targeting Calcineurin/Nfatc1 Signaling Sensitizes Proteasome Inhibition Treatment in Multiple Myeloma. HemaSphere, 6, 775–776. https://doi.org/10.1097/01.HS9.0000846408.90988.ee

Chicago

J. Zhang, X. Luo, T. Xia, K. C. Cheng, and M. H. Ng. 2022. “P883: Targeting Calcineurin/Nfatc1 Signaling Sensitizes Proteasome Inhibition Treatment in Multiple Myeloma.” HemaSphere 6 (June): 775–76. doi:10.1097/01.HS9.0000846408.90988.ee.